Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab - a translational project in the neoadjuvant GeparQuinto trial

Witzel, I.; Loibl, S.; von Minckwitz, G.; Eidtmann, H.; Fehm, T.; Khandan, F.; Schmatloch, S.; Hauschild, M.; Bischoff, J.; Fasching, P. A.; Mau, C.; Schem, C.; Rack, B.; Meinhold-Heerlein, I.; Liedtke, C.; Karn, T.; Huober, J.; zu Eulenburg, C.; Issa-Nummer, Y.; Untch, M.; Mueller, V.

dc.contributor.author	Fehm, Tanja
dc.date.accessioned	2014-03-06T10:50:25Z
dc.date.available	2014-03-06T10:50:25Z
dc.date.issued	2012
dc.identifier.issn	0007-0920
dc.identifier.uri	http://hdl.handle.net/10900/43032
dc.language.iso	en	en
dc.publisher	Nature Publishing Group	de_DE
dc.relation.uri	http://dx.doi.org/10.1038/bjc.2012.353	de_DE
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject.ddc	610	de_DE
dc.title	Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab - a translational project in the neoadjuvant GeparQuinto trial	de_DE
dc.type	Article	de_DE
utue.quellen.id	20140226071329_01035	de_DE
utue.publikation.seiten	956-960	de_DE
utue.personen.roh	Witzel, I.
utue.personen.roh	Loibl, S.
utue.personen.roh	von Minckwitz, G.
utue.personen.roh	Eidtmann, H.
utue.personen.roh	Fehm, T.
utue.personen.roh	Khandan, F.
utue.personen.roh	Schmatloch, S.
utue.personen.roh	Hauschild, M.
utue.personen.roh	Bischoff, J.
utue.personen.roh	Fasching, P. A.
utue.personen.roh	Mau, C.
utue.personen.roh	Schem, C.
utue.personen.roh	Rack, B.
utue.personen.roh	Meinhold-Heerlein, I.
utue.personen.roh	Liedtke, C.
utue.personen.roh	Karn, T.
utue.personen.roh	Huober, J.
utue.personen.roh	zu Eulenburg, C.
utue.personen.roh	Issa-Nummer, Y.
utue.personen.roh	Untch, M.
utue.personen.roh	Mueller, V.
dcterms.isPartOf.ZSTitelID	British Journal of Cancer	de_DE
dcterms.isPartOf.ZS-Issue	6	de_DE
dcterms.isPartOf.ZS-Volume	107	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE